MFDS Begins Preliminary Review of Russian COVID-19 Vaccine 'Covivac'

[Asia Economy Reporter Song Seung-yoon] The Ministry of Food and Drug Safety announced on the 20th that it has begun reviewing non-clinical data following a preliminary review application submitted by MP Corporation for the Russian-made CoviVac COVID-19 vaccine.

CoviVac is the third COVID-19 vaccine developed by Russia, created by the Chumakov Center for Research and Development of Immune-and-Biological Products under the Russian Academy of Sciences (hereinafter referred to as the Chumakov Center). Although the Korean government has not announced plans to import it, MP Corporation is leading domestic contract manufacturing.

The CoviVac vaccine is an inactivated vaccine that kills the virus and injects it as an antigen into the body to induce an immune response. It received emergency use authorization in Russia in February of this year but has not yet been approved in other countries.

This content was produced with the assistance of AI translation services.